EA201691529A1 - Гетероарильные амиды в качестве ингибиторов агрегации белков - Google Patents
Гетероарильные амиды в качестве ингибиторов агрегации белковInfo
- Publication number
- EA201691529A1 EA201691529A1 EA201691529A EA201691529A EA201691529A1 EA 201691529 A1 EA201691529 A1 EA 201691529A1 EA 201691529 A EA201691529 A EA 201691529A EA 201691529 A EA201691529 A EA 201691529A EA 201691529 A1 EA201691529 A1 EA 201691529A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- protein aggregation
- methods
- inhibitors
- parkinson
- Prior art date
Links
- 230000004845 protein aggregation Effects 0.000 title abstract 3
- -1 Heteroaryl Amides Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к некоторым гетероарильным амидным соединениям, к фармацевтическим композициям, содержащим их, и способам их применения, в том числе и к способам предотвращения, инвертирования, замедления или ингибирования агрегации белков, а также к способам лечения заболеваний, которые связаны с агрегацией белков, в том числе нейродегенеративных заболеваний, таких как болезнь Паркинсона, болезнь Альцгеймера, болезнь телец Леви, болезнь Паркинсона с деменцией, лобно-височная деменция, болезни Хантингтона, амиотрофический боковой склероз и множественная системная атрофия и злокачественные опухоли и меланома.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461933246P | 2014-01-29 | 2014-01-29 | |
US201462078895P | 2014-11-12 | 2014-11-12 | |
PCT/US2015/013263 WO2015116663A1 (en) | 2014-01-29 | 2015-01-28 | Heteroarly amides as inhibitors of protein aggregation |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691529A1 true EA201691529A1 (ru) | 2017-01-30 |
EA032374B1 EA032374B1 (ru) | 2019-05-31 |
Family
ID=52484559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691529A EA032374B1 (ru) | 2014-01-29 | 2015-01-28 | Гетероарильные амиды в качестве ингибиторов агрегации белков |
Country Status (37)
Country | Link |
---|---|
US (3) | US9738635B2 (ru) |
EP (2) | EP3348556B1 (ru) |
JP (2) | JP6619741B2 (ru) |
KR (1) | KR102383038B1 (ru) |
CN (2) | CN111039939B (ru) |
AP (1) | AP2016009347A0 (ru) |
AU (1) | AU2015211119B2 (ru) |
BR (2) | BR122018001892B1 (ru) |
CA (1) | CA2937967C (ru) |
CL (1) | CL2016001918A1 (ru) |
CR (1) | CR20160394A (ru) |
CY (2) | CY1120348T1 (ru) |
DK (2) | DK3348556T3 (ru) |
EA (1) | EA032374B1 (ru) |
EC (1) | ECSP16070327A (ru) |
ES (2) | ES2808978T3 (ru) |
HK (1) | HK1231470A1 (ru) |
HR (2) | HRP20180813T1 (ru) |
HU (2) | HUE050964T2 (ru) |
IL (1) | IL246987B (ru) |
LT (2) | LT3099684T (ru) |
ME (1) | ME03800B (ru) |
MX (1) | MX2016009896A (ru) |
MY (1) | MY187450A (ru) |
NZ (1) | NZ722487A (ru) |
PE (1) | PE20161393A1 (ru) |
PH (1) | PH12016501493A1 (ru) |
PL (2) | PL3348556T3 (ru) |
PT (2) | PT3099684T (ru) |
RS (2) | RS60547B1 (ru) |
SA (1) | SA516371579B1 (ru) |
SG (1) | SG11201606108RA (ru) |
SI (2) | SI3348556T1 (ru) |
TR (1) | TR201809440T4 (ru) |
UA (1) | UA118209C2 (ru) |
WO (1) | WO2015116663A1 (ru) |
ZA (1) | ZA201605246B (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60547B1 (sr) | 2014-01-29 | 2020-08-31 | UCB Biopharma SRL | Heteroaril amidi kao inhibitori proteinske agregacije |
US10975066B2 (en) | 2015-07-29 | 2021-04-13 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
CN107625767A (zh) * | 2016-11-25 | 2018-01-26 | 刘淑兰 | 一种治疗慢性盆腔炎的药物 |
MX2019008256A (es) | 2017-01-26 | 2019-09-09 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. |
AU2018212436A1 (en) | 2017-01-26 | 2019-07-25 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
ES2918048T3 (es) * | 2017-01-26 | 2022-07-13 | UCB Biopharma SRL | Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas |
JP7283699B2 (ja) * | 2017-05-12 | 2023-05-30 | マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 黒色腫の治療または予防において使用するためのフェニル-ヘテロ環-フェニル誘導体 |
JP2020529432A (ja) | 2017-08-04 | 2020-10-08 | アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. | 微生物により誘発されるアミロイドの阻害剤 |
EP3703730A4 (en) * | 2017-10-31 | 2022-01-12 | Loma Linda University | METHODS OF TREATMENT OF TRAUMATIC BRAIN DAMAGE |
JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解 |
CN118488951A (zh) * | 2021-12-27 | 2024-08-13 | 上海京新生物医药有限公司 | 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物 |
GB202213796D0 (en) * | 2022-09-21 | 2022-11-02 | Wista Lab Ltd | Tau aggregation inhibitors |
WO2024094731A1 (en) * | 2022-11-02 | 2024-05-10 | Ac Immune Sa | Novel compounds for the diagnosis of tdp-43 proteinopathies |
WO2024184179A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
WO2024184180A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
US7504410B2 (en) * | 2002-11-28 | 2009-03-17 | Schering Aktiengesellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
CN101385722A (zh) * | 2003-02-27 | 2009-03-18 | 乔安妮·麦克劳林 | 预防、治疗和诊断蛋白聚集疾病的方法 |
TW200530246A (en) * | 2003-12-19 | 2005-09-16 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
EP1697371B1 (en) * | 2003-12-19 | 2007-04-25 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
KR20070018824A (ko) * | 2003-12-19 | 2007-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클 |
WO2006021884A2 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
WO2006032322A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
SE0403119D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | Therapeutic agents |
JP2009505948A (ja) * | 2005-07-11 | 2009-02-12 | デブジェン エヌブイ | キナーゼ阻害剤としてのアミド誘導体 |
CN101233119A (zh) * | 2005-07-29 | 2008-07-30 | 4Sc股份有限公司 | 新型杂环NF-κB抑制剂 |
JP2009529555A (ja) * | 2006-03-15 | 2009-08-20 | 4エスツェー アクチェンゲゼルシャフト | 新規複素環式NF−κB阻害薬 |
JP2010510177A (ja) * | 2006-11-17 | 2010-04-02 | クイーンズ ユニバーシティ アット キングストン | タンパク質フォールディング障害を治療するための化合物および方法 |
EP2155226A4 (en) * | 2007-06-14 | 2010-07-28 | Univ California | COMPOUNDS FOR INHIBITING AGGREGATION OF PROTEINS AND METHODS OF MAKING AND USING SAME |
WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
CA2776480A1 (en) * | 2009-10-20 | 2011-04-28 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
RU2012129882A (ru) | 2009-12-16 | 2014-01-27 | Нейропор Терапиз, Инк. | Соединение |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
MX2014011615A (es) | 2012-03-28 | 2015-01-19 | Neuropore Therapies Inc | Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina. |
EP2872143B1 (en) * | 2012-07-16 | 2017-12-13 | Neuropore Therapies, Inc. | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
RS60547B1 (sr) | 2014-01-29 | 2020-08-31 | UCB Biopharma SRL | Heteroaril amidi kao inhibitori proteinske agregacije |
US10975066B2 (en) | 2015-07-29 | 2021-04-13 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
MX2019008256A (es) | 2017-01-26 | 2019-09-09 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. |
AU2018212436A1 (en) | 2017-01-26 | 2019-07-25 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
-
2015
- 2015-01-28 RS RS20200827A patent/RS60547B1/sr unknown
- 2015-01-28 EP EP18156929.4A patent/EP3348556B1/en active Active
- 2015-01-28 NZ NZ722487A patent/NZ722487A/en unknown
- 2015-01-28 ME MEP-2020-148A patent/ME03800B/me unknown
- 2015-01-28 HU HUE18156929A patent/HUE050964T2/hu unknown
- 2015-01-28 EP EP15705417.2A patent/EP3099684B8/en active Active
- 2015-01-28 PE PE2016001285A patent/PE20161393A1/es unknown
- 2015-01-28 ES ES18156929T patent/ES2808978T3/es active Active
- 2015-01-28 DK DK18156929.4T patent/DK3348556T3/da active
- 2015-01-28 LT LTEP15705417.2T patent/LT3099684T/lt unknown
- 2015-01-28 SG SG11201606108RA patent/SG11201606108RA/en unknown
- 2015-01-28 CN CN201911278647.XA patent/CN111039939B/zh active Active
- 2015-01-28 MY MYPI2016001401A patent/MY187450A/en unknown
- 2015-01-28 CA CA2937967A patent/CA2937967C/en active Active
- 2015-01-28 PL PL18156929T patent/PL3348556T3/pl unknown
- 2015-01-28 TR TR2018/09440T patent/TR201809440T4/tr unknown
- 2015-01-28 PT PT15705417T patent/PT3099684T/pt unknown
- 2015-01-28 UA UAA201609003A patent/UA118209C2/uk unknown
- 2015-01-28 RS RS20180644A patent/RS57533B1/sr unknown
- 2015-01-28 BR BR122018001892-5A patent/BR122018001892B1/pt active IP Right Grant
- 2015-01-28 DK DK15705417.2T patent/DK3099684T3/en active
- 2015-01-28 HU HUE15705417A patent/HUE040274T2/hu unknown
- 2015-01-28 CR CR20160394A patent/CR20160394A/es unknown
- 2015-01-28 AU AU2015211119A patent/AU2015211119B2/en active Active
- 2015-01-28 MX MX2016009896A patent/MX2016009896A/es active IP Right Grant
- 2015-01-28 SI SI201531297T patent/SI3348556T1/sl unknown
- 2015-01-28 ES ES15705417.2T patent/ES2675301T3/es active Active
- 2015-01-28 BR BR112016017344-9A patent/BR112016017344B1/pt active IP Right Grant
- 2015-01-28 LT LTEP18156929.4T patent/LT3348556T/lt unknown
- 2015-01-28 JP JP2016549488A patent/JP6619741B2/ja active Active
- 2015-01-28 EA EA201691529A patent/EA032374B1/ru unknown
- 2015-01-28 CN CN201580017216.1A patent/CN106132960B/zh active Active
- 2015-01-28 AP AP2016009347A patent/AP2016009347A0/en unknown
- 2015-01-28 WO PCT/US2015/013263 patent/WO2015116663A1/en active Application Filing
- 2015-01-28 PL PL15705417T patent/PL3099684T3/pl unknown
- 2015-01-28 KR KR1020167023810A patent/KR102383038B1/ko active IP Right Grant
- 2015-01-28 PT PT181569294T patent/PT3348556T/pt unknown
- 2015-01-28 SI SI201530252T patent/SI3099684T1/en unknown
- 2015-12-29 US US14/983,243 patent/US9738635B2/en active Active
-
2016
- 2016-07-27 IL IL246987A patent/IL246987B/en unknown
- 2016-07-28 CL CL2016001918A patent/CL2016001918A1/es unknown
- 2016-07-28 ZA ZA2016/05246A patent/ZA201605246B/en unknown
- 2016-07-28 SA SA516371579A patent/SA516371579B1/ar unknown
- 2016-07-28 PH PH12016501493A patent/PH12016501493A1/en unknown
- 2016-08-29 EC ECIEPI201670327A patent/ECSP16070327A/es unknown
-
2017
- 2017-05-18 HK HK17105014.2A patent/HK1231470A1/zh unknown
- 2017-08-01 US US15/666,503 patent/US10358443B2/en active Active
-
2018
- 2018-05-24 HR HRP20180813TT patent/HRP20180813T1/hr unknown
- 2018-06-15 CY CY20181100630T patent/CY1120348T1/el unknown
-
2019
- 2019-06-04 JP JP2019104159A patent/JP6783900B2/ja active Active
- 2019-06-11 US US16/438,348 patent/US11078196B2/en active Active
-
2020
- 2020-07-14 HR HRP20201107TT patent/HRP20201107T8/hr unknown
- 2020-07-24 CY CY20201100682T patent/CY1123374T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691529A1 (ru) | Гетероарильные амиды в качестве ингибиторов агрегации белков | |
MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
EA201990221A1 (ru) | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
BR112018069533A2 (pt) | tratamento de condições alérgicas oculares com ciclodextrinas | |
SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
EA201891526A3 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201592024A1 (ru) | Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны | |
JO3458B1 (ar) | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 | |
MX2019008256A (es) | Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas. | |
EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
EA202090414A1 (ru) | Соединения и их применение | |
TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
EA201990399A1 (ru) | Соединения, композиции и их применение | |
EA201790315A1 (ru) | Модуляторы x-рецепторов печени |